Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematopoietic Regulation and Myeloproliferative Neoplasm Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SH2B3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SH2B3 (LNK) Recombinant Protein (SH2 Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or Insect cell expressed. |
View SH2B3 Products |
| Gene Delivery | SH2B3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression assays. |
View SH2B3 Products |
| Benchmark Ab | Anti-SH2B3 Recombinant Antibody Sequence-verified positive control for Western Blot and IP validation. |
View SH2B3 Products |
| Validator | SH2B3 siRNA Set Target-specific knockdown verification in hematopoietic cell lines. |
View SH2B3 Products |
| Related Target A | JAK2 Primary downstream kinase regulated by SH2B3; critical for MPN pathway screening. |
View JAK2 Products |
| Related Target B | MPL (TPO Receptor) Key receptor interacting with SH2B3 to control megakaryopoiesis and stem cell self-renewal. |
View MPL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Screening (SH2B3-JAK2) | High-purity recombinant SH2B3 SH2-domain proteins with precise sequence verification for SPR/BLI binding assays. |
| Cellular Overexpression & Signaling Validation | Lentiviral particles carrying full-length SH2B3 ORF for stable expression in TF-1 or HEL cell lines. |
| Lack of Controls | Recombinant sequence-verified benchmark antibodies included for assay standardization. |
| False Positives in Knockdown | Chemically synthesized siRNA pools validated for specific transcript depletion. |
Live SH2B3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SH2B3 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to targeted protein-protein interaction (PPI) modulators and genetic therapies. As first-generation JAK inhibitors face resistance in myeloproliferative neoplasms (MPNs), the next wave of R&D is targeting the SH2B3-JAK2 axis to restore physiological negative feedback. Additionally, transient inhibition of SH2B3 represents a breakthrough strategy in ex vivo hematopoietic stem cell (HSC) expansion for bone marrow transplantation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Medical Centers, Biotech Startups | Myeloproliferative Neoplasms (MPN), Erythrocytosis | In vitro binding assays requiring high-purity SH2B3 SH2 domain recombinant proteins. |
| siRNA / RNAi Therapeutics | Hematology Research Institutes | Ex Vivo Hematopoietic Stem Cell Expansion | Targeted knockdown validation requiring sequence-specific siRNA controls. |
| Gene Editing / CRISPR | Cell Therapy Developers | Refractory Leukemias, Stem Cell Engraftment | Lentivirus-mediated rescue assays to confirm target specificity and off-target profiles. |